Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time. Those medications, however, are not without their risks and side effects.

The UK’s National Institute for Health and Care Excellence (NICE) has issued further draft guidance reaffirming its decision ...

Systematic fraud -- led by a "cabal of self-interested researchers, government accomplices, and corporate greed" in the words ...

NICE is seeking public comment on the updated draft guidances through March 27, with plans to issue final draft guidances in July.

Two medications are currently approved for Alzheimer’s treatment in the U.S. — lecanemab (Leqembi) and donanemab (Kisunla). Both are monoclonal antibodies that are administered via IV infusions. They ...

"I think it helped," says her husband, Ken Bell. "But I'm not sure." That sort of uncertainty is common when it comes to Leqembi and Kisunla, two new Alzheimer's drugs approved since 2023. Both drugs ...

US-based Eli Lilly's Kisunla drug and Japanese company Eisai's Leqembi (below), two breakthrough drugs for the diagnosis and ...

Both Kisunla and the other approved drug, Leqembi, have been shown to slow down the mental decline of Alzheimer’s by more than 25%. But that’s in a group of patients—an individual may do much better, ...

Meanwhile, it could also help offset concerns that the rate of ARIA-E and ARIA-H are a little higher with Kisunla than with Leqembi. The company said it plans to submit the TRAILBLAZER-ALZ 6 data ...

"But I'm not sure." That sort of uncertainty is common when it comes to Leqembi and Kisunla, two new Alzheimer's drugs approved since 2023. Both drugs clear the brain of a substance called beta ...

Leqembi, marketed by Biogen and Eisai, was first rejected for NHS coverage in August 2024, while a negative coverage decision for Eli Lilly’s Kisunla came in October 2024. Following a request ...